Profile data is unavailable for this security.
About the company
Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
- Revenue in SEK (TTM)0.00
- Net income in SEK-30.59m
- Incorporated2021
- Employees2.00
- LocationBiosergen ABFogdevreten 2SOLNA 171 65SwedenSWE
- Websitehttps://biosergen.net/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chosa Oncology AB | 717.00k | -6.01m | 62.72m | -- | -- | 3.89 | -- | 87.48 | -0.0766 | -0.0766 | 0.0096 | 0.2044 | 0.0382 | -- | 0.8639 | -- | -32.00 | -55.65 | -35.30 | -67.69 | 643.24 | -- | -837.66 | -792.50 | -- | -49.05 | 0.00 | -- | -39.73 | -62.56 | 59.93 | -- | -- | -- |
| Lifecare ASA | 1.68m | -114.22m | 74.80m | 28.00 | -- | -- | -- | 44.41 | -2.48 | -2.48 | 0.0379 | -0.11 | 0.0168 | -- | 0.1582 | 55,272.73 | -115.30 | -52.64 | -194.19 | -61.98 | -- | -- | -6,864.75 | -277.39 | -- | -- | 1.17 | -- | -26.10 | 36.13 | -103.52 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.05m | -28.49m | 79.39m | 8.00 | -- | 4.77 | -- | 75.61 | -0.058 | -0.058 | 0.0021 | 0.0251 | 0.0326 | -- | 10.14 | 80,769.23 | -88.56 | -24.44 | -104.41 | -25.71 | -- | -- | -2,713.71 | -3,325.49 | -- | -- | 0.00 | -- | 58.85 | 129.52 | 23.01 | -- | -- | -- |
| Opsy Holding AB | 4.13m | -18.69m | 82.53m | 7.00 | -- | 53.44 | -- | 19.99 | -20.83 | -20.83 | 0.6321 | 0.1216 | 0.294 | -- | 7.63 | 2,064,500.00 | -133.11 | -117.68 | -201.35 | -142.11 | 154.30 | -- | -452.72 | -- | -- | -216.84 | 0.463 | -- | -- | -- | -43.22 | -- | -- | -- |
| IDL Diagnostics AB (publ) | 52.19m | -39.31m | 84.31m | 22.00 | -- | 0.5635 | -- | 1.62 | -0.1706 | -0.1706 | 0.2266 | 0.6495 | 0.3263 | 6.59 | 5.26 | 2,372,364.00 | -24.58 | -29.04 | -26.98 | -31.14 | 21.53 | 1.70 | -75.32 | -157.60 | 3.29 | -- | 0.0843 | -- | 33.45 | 164.62 | 28.41 | -- | 18.85 | -- |
| Alligator Bioscience AB | 42.25m | -77.72m | 94.82m | 13.00 | -- | -- | -- | 2.24 | -2.16 | -2.16 | 0.6369 | -0.0592 | 0.5013 | -- | 9.35 | 938,822.30 | -92.22 | -97.96 | -- | -155.50 | -- | -- | -183.96 | -569.04 | -- | -- | 1.33 | -- | -0.5851 | 67.68 | 5.91 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -20.64m | 100.26m | 3.00 | -- | 8.61 | -- | -- | -0.7859 | -0.7859 | 0.00 | 0.4681 | 0.00 | -- | -- | 0.00 | -85.07 | -133.34 | -91.51 | -179.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.00 | -- | -- | -- |
| Active Biotech AB publ | 0.00 | -38.50m | 101.75m | 5.00 | -- | 13.30 | -- | -- | -0.0737 | -0.0737 | 0.00 | 0.0029 | 0.00 | -- | -- | 0.00 | -241.37 | -94.38 | -927.66 | -120.44 | -- | -- | -- | -3,355.24 | -- | -- | 0.0816 | -- | -- | -- | 13.98 | -- | -- | -- |
| Biosergen AB | 0.00 | -30.59m | 102.38m | 2.00 | -- | 5.05 | -- | -- | -13.74 | -13.74 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -152.65 | -- | -191.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.00 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -38.73m | 108.71m | 4.00 | -- | 3.07 | -- | -- | -6.65 | -6.65 | 0.00 | 5.02 | 0.00 | -- | -- | 0.00 | -113.73 | -145.61 | -127.96 | -179.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.07 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -66.67m | 110.99m | 12.00 | -- | 1.78 | -- | -- | -1.40 | -1.40 | 0.00 | 1.07 | 0.00 | -- | -- | 0.00 | -108.82 | -43.50 | -168.39 | -50.76 | -- | -- | -- | -- | -- | -20.18 | 0.0052 | -- | -- | -- | -8.27 | -- | 1.47 | -- |
| Glycorex Transplantation AB (publ) | 39.94m | -7.06m | 118.67m | 20.00 | -- | 3.33 | 50.43 | 2.97 | -0.0917 | -0.0917 | 0.5174 | 0.4719 | 0.7442 | 1.45 | 5.20 | 1,997,000.00 | -13.15 | -15.79 | -17.51 | -18.66 | 81.68 | 87.06 | -17.67 | -44.85 | 1.56 | -15.83 | 0.1599 | -- | 17.35 | -0.5296 | 63.97 | -- | -- | -- |
| Abera Bioscience AB | 0.00 | -1.45m | 120.16m | 5.00 | -- | 4.28 | -- | -- | -0.0872 | -0.0872 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -6.61 | -68.96 | -7.94 | -85.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 93.42 | -- | -- | -- |
| Biovica International AB | 9.86m | -76.47m | 120.58m | 24.00 | -- | 1.03 | -- | 12.22 | -0.6375 | -0.6375 | 0.0684 | 0.4241 | 0.0799 | 12.71 | 4.46 | 365,333.30 | -61.92 | -58.22 | -70.41 | -66.49 | -171.53 | -462.09 | -775.22 | -1,804.16 | 8.11 | -- | 0.0239 | -- | 18.23 | 38.83 | 29.80 | -- | -47.26 | -- |
| Alzinova AB | 205.00k | -26.88m | 129.36m | 5.00 | -- | 0.6324 | -- | 631.03 | -0.2846 | -0.2846 | 0.0022 | 1.23 | 0.0015 | -- | 0.3254 | 41,000.00 | -19.42 | -12.21 | -20.69 | -12.85 | -5,834.15 | -- | -13,114.15 | -21,390.81 | -- | -1,794.80 | 0.0062 | -- | -88.89 | -- | -24.71 | -- | 19.48 | -- |
| SoftOx Solutions AS | 12.55m | -2.77m | 134.65m | 5.00 | -- | 1.37 | 181.05 | 10.73 | -0.001 | -0.001 | 0.0065 | 0.0445 | 0.123 | -- | 30.13 | 2,717,798.00 | -2.72 | -50.91 | -3.22 | -67.07 | -- | -- | -22.07 | -644.92 | 1.16 | -3.92 | 0.1212 | -- | 13.38 | 14.06 | -8.86 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Biosergen AB's reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 430.00 | 0.02% |
Data from 30 Dec 2025 - 30 Dec 2025Source: FactSet Research Systems Inc.
